TriangleNCT01602666 · OUTCOME
Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 3 years
What was measured
Kaplan Meier estimate of the 3-year PFS rate is provided. PFS is the time interval measured from initiation of treatment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
Analysis population: The eligible patients with localized germinoma and CSF serum hCGbeta of 50 mIU/mL or less or CSF serum hCGbeta greater than 50 mIU/mL and less than or equal to 100 mIU/mL.
Groups in this outcome
hCGbeta <= 50 mIU/mL
CSF/serum hCGbeta \<= 50 mIU/mL
50 mIU/mL < hCGbeta <= 100 mIU/mL
50 mIU/mL \< CSF /serum hCGbeta \<= 100 mIU/mL
| Group | Source count |
|---|---|
| hCGbeta <= 50 mIU/mL | 131 |
| 50 mIU/mL < hCGbeta <= 100 mIU/mL | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| hCGbeta <= 50 mIU/mL | 93.26 | Not reported | 86.95 | 96.58 | Not reported |
| 50 mIU/mL < hCGbeta <= 100 mIU/mL | 80.00 | Not reported | 20.38 | 96.92 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 86.95
- upper Limit
- 96.58
- value
- 93.26
- group Id
- OG001
- lower Limit
- 20.38
- upper Limit
- 96.92
- value
- 80.00
- denoms
- counts
- group Id
- OG000
- value
- 131
- group Id
- OG001
- value
- 6
- units
- Participants
- description
- Kaplan Meier estimate of the 3-year PFS rate is provided. PFS is the time interval measured from initiation of treatment until progression or death from any cause or until last follow-up for those who were event free at the time of analysis. Patients who were lost to follow-up or withdrew consent were censored in this analysis. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\>25% increase in 2D or \>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- CSF/serum hCGbeta \<= 50 mIU/mL
- id
- OG000
- title
- hCGbeta <= 50 mIU/mL
- description
- 50 mIU/mL \< CSF /serum hCGbeta \<= 100 mIU/mL
- id
- OG001
- title
- 50 mIU/mL < hCGbeta <= 100 mIU/mL
- param Type
- NUMBER
- population Description
- The eligible patients with localized germinoma and CSF serum hCGbeta of 50 mIU/mL or less or CSF serum hCGbeta greater than 50 mIU/mL and less than or equal to 100 mIU/mL.
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
- type
- SECONDARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice